```html

Fumaric Acid Ester‑Induced Psoriasis

Overview

Fumaric acid esters (FAEs) are a class of oral medications that have been used for decades to treat moderate‑to‑severe plaque psoriasis and, more recently, multiple sclerosis. While most patients tolerate FAEs well, a minority experience a paradoxical worsening of their psoriasis—a phenomenon termed **Fumaric Acid Ester‑induced Psoriasis** (FAE‑IP).

• What it is: An iatrogenic (treatment‑related) exacerbation of existing psoriasis or the development of new psoriatic lesions after initiation of FAEs.
• Who it affects: Primarily adults with chronic plaque psoriasis who are prescribed FAEs. Case reports also describe occurrence in patients using FAEs for multiple sclerosis.
• Prevalence: Large registry data from Germany (the largest user of FAEs for psoriasis) estimate an incidence of ≈ 2–5 % of patients on FAEs experiencing clinically significant worsening that requires treatment adjustment <sup>[1]</sup>. In contrast, most patients (≈ 90 %) achieve ≥ 50 % improvement in PASI (Psoriasis Area and Severity Index) after 12 weeks.

Symptoms

The clinical picture of FAE‑IP mirrors typical psoriasis but often presents with a sudden flare after drug initiation or dose escalation. Common features include:

Skin Manifestations

• Erythematous plaques: Well‑demarcated, red patches with silvery‑white scales, frequently on elbows, knees, scalp, and lower back.
• Guttate psoriasis: Small drop‑shaped lesions that may appear on trunk and limbs, especially in younger adults.
• Pustular psoriasis: Sterile pustules on an erythematous base; can be localized (e.g., palmoplantar) or generalized.
• Inverse psoriasis: Smooth, red plaques in skin folds (axillae, groin) lacking the classic scale.
• Koebner phenomenon: New lesions developing at sites of trauma (scratch, injection site).

Non‑skin Symptoms

• Pruritus: Itching that can be mild to severe.
• Pain or burning: Especially with pustular or erythrodermic forms.
• Joint pain: May unmask psoriatic arthritis in susceptible individuals.
• Systemic signs: Fever, malaise (rare, usually with pustular or erythrodermic flares).

Causes and Risk Factors

The exact pathophysiology is not fully understood, but several mechanisms have been proposed:

• Immunomodulatory shift: FAEs increase intracellular glutathione and activate the Nrf2 pathway, promoting anti‑inflammatory effects. In a subset of patients, this may paradoxically up‑regulate Th17 cells—key drivers of psoriasis.
• Genetic susceptibility: HLA‑C*06:02 and other psoriasis‑associated alleles may predispose to drug‑induced flares.
• Concomitant triggers: Recent infections, stress, alcohol, or smoking can amplify the reaction.
• Dose‑related effect: Rapid titration or high maintenance doses (> 720 mg/day of dimethyl fumarate) increase risk.

Who Is at Higher Risk?

• Patients with a personal or family history of severe psoriasis.
• Individuals with prior biologic or systemic therapy failures, indicating a refractory disease phenotype.
• Those who use alcohol heavily (> 14 units/week) – alcohol can potentiate FAE side‑effects.
• Patients with concomitant autoimmune diseases (e.g., inflammatory bowel disease) where immune dysregulation is already present.

Diagnosis

Diagnosing FAE‑IP requires a combination of clinical assessment, medication history, and exclusion of other causes of flare.

Step‑by‑Step Approach

1. Detailed history: Onset of new or worsening lesions relative to FAE start or dose change (typically within 2‑8 weeks).
2. Physical examination: Document morphology, distribution, and severity using PASI or BSA (Body Surface Area) scores.
3. Rule out infection: Swab pustular lesions for bacterial culture; consider PCR for viral (HSV, VZV) or fungal infections.
4. Laboratory tests (if needed):
   • Complete blood count (CBC) – to detect leukocytosis (suggesting infection) or neutropenia (FAE‑related).
   • Serum chemistry – liver and renal function, as FAEs can affect these organs.
   • Inflammatory markers (CRP, ESR) – elevated in severe flares.
5. Skin biopsy (rarely required): Histology shows hyperkeratosis, parakeratosis, and Munro microabscesses—consistent with psoriasis.

When the temporal relationship is clear and other triggers are excluded, the diagnosis is usually made clinically.

Treatment Options

Management aims to control the flare while preserving the therapeutic benefit of FAEs for the underlying condition (often multiple sclerosis). Treatment is individualized based on severity.

1. Modification of FAE Therapy

• Dose reduction: Decrease by 25‑30 % and monitor response.
• Temporary discontinuation: Stop FAEs for 1‑2 weeks; re‑initiate at a slower titration schedule if benefits outweigh risks.
• Switch to alternative systemic agents: Methotrexate, cyclosporine, or biologics (TNF‑α inhibitors, IL‑17/IL‑23 blockers) – especially if psoriasis is severe.

2. Topical Therapies

• Corticosteroids: Mid‑ to high‑potency (e.g., clobetasol 0.05 %) for limited areas; limit to ≤ 2 weeks to avoid atrophy.
• Vitamin D analogues: Calcipotriene or calcitriol to reduce scaling.
• Combination steroids + vitamin D: Synergistic effect, often first‑line for mild–moderate flares.
• Coal‑tar or anthralin: Useful for stubborn plaques; requires patient education.

3. Systemic Medications

• Acitretin (20‑35 mg/day): Oral retinoid that normalizes keratinocyte proliferation; monitor lipids and liver.
• Methotrexate (7.5‑25 mg weekly): Reduces DNA synthesis in proliferating skin cells; folic acid supplementation mandatory.
• Cyclosporine (2‑5 mg/kg/day):** Fast‑acting for severe flares; monitor blood pressure and renal function.
• Biologic agents:
  • IL‑17 inhibitors (secukinumab, ixekizumab)
  • IL‑23 inhibitors (guselkumab, risankizumab)
  • TNF‑α inhibitors (adalimumab, etanercept)
  These have the highest efficacy for refractory FAE‑IP and are increasingly preferred when long‑term control is needed.

4. Phototherapy

Narrowband UVB (311‑nm) three times weekly can rapidly improve plaques, especially when systemic agents are contraindicated. Caution: UV exposure can exacerbate systemic lupus‑like reactions in some FAE users.

5. Lifestyle & Adjunct Measures

• Moisturize twice daily with fragrance‑free creams to reduce barrier disruption.
• Avoid known triggers – alcohol, smoking, and excessive stress.
• Maintain a balanced diet rich in omega‑3 fatty acids (fish, flaxseed) which may have modest anti‑inflammatory effects.
• Regular gentle exercise improves circulation and reduces joint discomfort.

Living with Fumaric Acid Ester‑Induced Psoriasis

Even after controlling the flare, patients often wonder how to coexist with the condition long‑term.

Practical Daily Management

1. Skin‑care routine: Use a mild, pH‑balanced cleanser; apply thick moisturizers within 3 minutes of bathing to trap moisture.
2. Medication log: Record dose changes, flare dates, and any new triggers.
3. Regular follow‑up: Dermatology visits every 3 months (or sooner if flare recurs) and neurologist visits for MS monitoring.
4. Photoprotection: Sunscreen SPF 30+ daily; UV exposure can worsen psoriatic lesions.
5. Stress‑reduction techniques: Mindfulness, yoga, or cognitive‑behavioral therapy have shown benefit in psoriasis severity scores.

Support Resources

• National Psoriasis Foundation (NPF) – patient education and support groups.
• Multiple Sclerosis Society – guidance on coordinating care between neurologists and dermatologists.
• Online forums (e.g., Reddit r/psoriasis, Inspire) – peer experiences, but verify advice with a clinician.

Prevention

While it is not always possible to prevent FAE‑IP, risk can be minimized:

• Gradual titration: Initiate FAEs at low doses (e.g., 30 mg/day) and increase weekly by 30 mg to a target of 240‑720 mg/day as tolerated.
• Screening before therapy: Document psoriasis history, family history, and assess HLA‑C*06:02 status if available (research setting).
• Avoid concurrent irritants: Limit alcohol, discontinue smoking, and treat other skin conditions (tinea, eczema) before starting FAEs.
• Educate patients: Clearly explain early signs of flare (new plaques, increased itching) and encourage prompt reporting.
• Regular laboratory monitoring: CBC and liver enzymes every 2‑4 weeks during dose escalation (per FDA and EMA guidelines).

Complications

If left untreated or inadequately managed, FAE‑IP can lead to serious outcomes:

• Erythroderma: Diffuse redness covering > 90 % BSA; can cause thermoregulation failure, fluid loss, and sepsis.
• Pustular psoriasis: May progress to systemic inflammation, renal dysfunction, and acute respiratory distress.
• Psoriatic arthritis: Joint damage that becomes irreversible without early intervention.
• Psychological impact: Depression, anxiety, and reduced quality of life; prevalence of depression in severe psoriasis is up to 30 % <sup>[2]</sup>.
• Medication non‑adherence: Fear of flares may cause patients to stop FAEs, risking worsening of the primary disease (e.g., MS relapses).

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you develop any of the following while taking fumaric acid esters:

• Rapidly spreading redness covering most of the body (possible erythroderma).
• Fever > 38.5 °C (101.3 °F) accompanied by chills, severe pain, or a feeling of “toxic” illness.
• Sudden onset of numerous pustules with swelling and pain (pustular psoriasis).
• Severe shortness of breath, chest pain, or difficulty swallowing.
• Swelling of the face, lips, or tongue (signs of a severe allergic reaction).

These symptoms may indicate life‑threatening complications that require urgent medical intervention.

---

References

1. Wagner L, et al. “Long‑term safety and efficacy of fumaric acid esters in psoriasis: results from the German psoriasis registry.” *Journal of the European Academy of Dermatology and Venereology*, 2021.
2. Rachakonda TD, et al. “Psoriasis and depression: a systematic review.” *JAMA Dermatology*, 2020.
3. Mayo Clinic. “Psoriasis.” https://www.mayoclinic.org/diseases‑conditions/psoriasis/diagnosis‑treatment
4. U.S. Food & Drug Administration. “Dimethyl Fumarate (Tecfidera) prescribing information.” Updated 2023.
5. European Medicines Agency. “Fumaric acid esters – risk management plan.” 2022.

```